AMA outlines strategy for health equity

The American Medical Association (AMA) has adopted a policy to define health equity while outlining a strategy for achieving optimized care in all aspects of health. 

Addressing the current gaps in health and healthcare across America, the AMA aims to develop an organizational home with dedicated servers, staff and budget. The strategic framework, aimed at achieving health equity, presented by the AMA includes:

  • Advocating for improved healthcare access, research, and data collection.
  • Promoting equity in care.
  • Increasing health workforce diversity and cultural awareness/competency.
  • Influencing determinants of health.
  • Voicing a commitment to health equity.

“We believe all Americans should have access to affordable and meaningful health care,” said AMA Board Member Willarda V. Edwards, MD, MBA. “There are myriad reasons for health disparities and health inequity, including juvenile justice, bias, stereotyping, prejudice and clinical uncertainty, to the fact that chronic diseases like diabetes and hypertension disproportionately affect minority populations. We know that overwhelmingly, America’s physician workforce entered the field driven by a desire to help people. By stepping back, cutting through the rhetoric and working collaboratively, we can ensure meaningful access to care for all Americans and improve the health of our nation.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.